How To Narrow The Evidence Gap For Histology Independent Drugs
Executive Summary
Conditional reimbursement arrangements could be hindering health technology assessment bodies from introducing long-term methodological changes that could help them better address histology independent drugs, finds a new report from the Office of Health Economics.